IL1 blockade in crystal-induced arthritis: impact of disease duration and the inflammatory syndrome. Comments on the article by Couderc M. et al. "Efficacy of anakinra in articular chondrocalcinosis".

[1]  S. Mathieu,et al.  Efficacy of anakinra in articular chondrocalcinosis: report of three cases. , 2012, Joint, bone, spine : revue du rhumatisme.

[2]  C. Mancuso,et al.  Anakinra's efficacy is variable in refractory gout: report of ten cases. , 2010, Seminars in arthritis and rheumatism.

[3]  A. Olivé,et al.  Anti-IL-1 molecules: new comers and new indications. , 2010, Joint, bone, spine : revue du rhumatisme.

[4]  C. Gabay,et al.  Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. , 2009, Joint, bone, spine : revue du rhumatisme.

[5]  P. Emery,et al.  Successful treatment of resistant pseudogout with anakinra. , 2008, Arthritis and rheumatism.

[6]  J. Tschopp,et al.  A pilot study of IL-1 inhibition by anakinra in acute gout , 2007, Arthritis research & therapy.